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Background: Persistent airflow limitation is common among patients with severe
asthma, but its pathogenesis has not been fully clarified. Severe alpha-1-antitrypsin
(AAT) deficiency is a risk factor of chronic airflow limitation and emphysema, and
partially deficient phenotypes have been associated with an accelerated decline in
lung function. We hypothesized that partial deficiency of AAT (non-PiM AAT
phenotype) is a risk factor of persistent airflow limitation in asthma.
Methods: In 122 patients with severe asthma (86 females; age (median (range)):
44.0 yr (18–75)) postbronchodilator FEV1 and FEV1/VC were measured and the AAT
phenotype was determined. Persistent airflow limitation was defined as post-
bronchodilator FEV1 or FEV1/VCo75% pred. with TLC475% pred.
Results: Six patients (4.9%) had a non-PiM phenotype (1 MF, 3 MS, 1 MZ and 1 SZ). Of
the 58 patients with persistent airflow limitation only 1 patient (1.7%) had a non-PiM
phenotype vs. 7.8% among the patients without persistent airflow limitation
(P ¼ 0:21). Postbronchodilator FEV1/VC (% pred.) was higher in the non-PiM patients
than in the PiM patients (P ¼ 0:02), the other lung function parameters were not
different. Linear regression analysis showed no association between AAT phenotype
and FEV1% predicted (P ¼ 0:26).
Conclusions: AAT heterozygoty does not seem to be an important risk factor of
persistent airflow limitation in patients with asthma. Although confirmation by
longitudinal follow-up studies with larger sample sizes is needed, these results
suggest that routine assessment of the AAT phenotype is not indicated in asthmatic
patients even if they exhibit fixed airflow limitation.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
5262950; fax: +31 71 5266927.
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Deficient AAT phenotypes and persistent airflow limitation 1535Introduction siveness to inhaled histamine. They were treatedPersistent airflow limitation is commonly found (up
to 50%) in adult patients with severe asthma1 and
has been reported to be associated with overall
mortality.2,3 Patients with asthma have a faster
decline in FEV1 than healthy subjects.
4 Several
factors have been suggested to contribute to the
decline in lung function in asthma, including
smoking,4 adult onset of asthma1,5–7 severe airway
hyperresponsiveness1,8,9 and persistent eosinophi-
lic airway inflammation.1,5,10,11 However, there
might be additional factors to be taken into
consideration.
Alpha-1-antitrypsin (AAT) is an inhibitor of
leukocyte proteases, and deficiency of this serpin
is known to predispose to the development of
chronic airflow limitation and emphysema.12–14 Not
only the homozygous PiZZ-AAT phenotype, but also
the PiMZ phenotype has been related to a more
rapid decline in FEV1 in patients with chronic
airflow limitation.15 In addition, AAT heterozygous
phenotypes have been shown to be associated with
bronchial hyperresponsiveness16,17 and asthma
symptoms are common among patients with severe
AAT-deficiency.18–20
In the present study we hypothesized that a
heterozygous (non-PiM) AAT phenotype is a risk
factor of persistent airflow limitation in patients
with asthma. To test this hypothesis we assessed
the prevalence of a non-PiM phenotype in patients
with severe asthma with or without persistent
airflow limitation, compared lung function para-
meters between PiM and non-PiM phenotypes, and
analysed whether a non-PiM phenotype was asso-
ciated with a more impaired lung function as
compared to a PiM AAT phenotype.Methods
Subjects
A cohort of 136 patients with severe asthma who
were participating in studies aimed at identifying
clinical phenotypes of severe asthma1 was re-
cruited in 1998 and 1999. Of these, blood samples
of 122 patients were available for analysis in the
current study. The patients were consecutively
enrolled from the outpatient pulmonary depart-
ments of 2 teaching and 8 non-teaching hospitals in
the western part of the Netherlands. They had a
history of episodic dyspnea and wheezing, a
documented (recently or in the past) reversibility
in FEV1 of 412% predicted and/or hyperrespon-with inhaled corticosteroids (X1600 mg/day beclo-
metasone or equivalent) and long-acting broncho-
dilators for more than one year. Thirty-eight out of
122 patients were on daily oral prednisone X5mg/
day. All patients were symptomatic and had at least
1 severe exacerbation during the past year requir-
ing a course of oral corticosteroids. All patients
were non-smokers, and 38.5% had smoked in the
past (maximum allowed smoking history of 10 pack
years). At the time of study-entry patients had to
be clinically stable for at least 1 month and not
have used a course of oral steroids or antibiotics in
this month previous to the study. The study was
approved by the Ethics Committee of the Leiden
University Medical Center.
Design
On 1 single day, lung function measurements were
performed, blood samples were drawn, and a short
questionnaire was taken. This questionnaire was
used to assess patient characteristics such as
severity of symptoms, medication usage and dura-
tion of asthma. The latter was estimated from the
first attack of dyspnea or wheezing ever.
Measurements AAT phenotyping
AAT-phenotype was determined by analysis of
serum samples using iso-electric focusing. Lung function
FEV1 and slow vital capacity (sVC) measurements
were performed before and 30min after inhala-
tion of 400 mg salbutamol and 80 mg ipratropium
bromide through a volume spacer according to
standard methods, using a dry rolling seal
spirometer. Functional residual capacity (FRC)
and total lung capacity (TLC) were measured by
the multiple breath helium equilibrium method
and carbon monoxide diffusing capacity (KCO) by
the single breath method. Predicted values were
obtained from Quanjer and co-workers.21,22
Persistent airflow limitation was defined as
postbronchodilator FEV1 or FEV1/VCo75% pre-
dicted with TLC475% predicted.
Analysis
Non-parametric tests and w2 analysis were used to
assess differences in patient characteristics be-
tween patients with a PiM-phenotype and a non-PiM
phenotype. Logistic regression analysis was used to
assess the association between a (non-) PiM
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tent airflow limitation (dependent factor) cor-
rected for age, gender, and duration of asthma.
Multivariate linear regression analysis was used to
determine the association between postbronchodi-
lator FEV1 and FEV1/VC % predicted and AAT
phenotype (corrected for age, sex and duration of
asthma). The relationship between asthma dura-
tion and postbronchodilator FEV1 (%pred) and FEV1/
VC (%pred) was investigated by linear regression
analyses and Pearson’s correlation coefficients.
Slopes of the regression lines (b: estimated regres-
sion weight) were interpreted as the estimated
annual decline in lung function.23 All analyses were
performed using the Statistical Package of the
Social Sciences (SPSS-11.0). P-values less than 0.05
were considered statistically significant.Figure 1 Prevalence of non-PIM phenotype in patients
with and without persistent airflow limitation.Results
Prevalence of AAT phenotypes
Characteristics of the participating patients are
summarized in Table 1. Amongst the 122 patients
with severe asthma 6 patients (4.9%, CI: 1.0–8.8%)
with a non-PiM AAT phenotype were identified: 1
MF, 3 MS, 1 MZ and 1 SZ.
Persistent airflow limitation
Fifty-eight patients (47.5%, CI: 39–57%) were
diagnosed with persistent airflow limitation. In this
group only 1 patient (1.7%) had a non-PiM pheno-
type, compared to 5 out of 64 patients (7.8%) in the
group without persistent airflow limitation (Fig. 1).
There was no association between the presence
of a non-PiM phenotype and the presence of
persistent airflow limitation (corrected for age,
gender and asthma duration), P ¼ 0:22 (OR 0.24
(CI: 0.02–2.31)).Table 1 Patient characteristics according to Pi-type.
non-PiM (n ¼ 6)
Age (yr) 37.0 (18–56)
Gender (% female) 66.7
Asthma duration (yr) 13.5 (6–56)
pb-FEV1 (%pred.) 96.5 (42.2–132.3)
pb-FEV1/VC (%pred.) 105.4 (56.4–111.9)
RV/TLC (%pred.) 96.0 (66.7–114.3)
KCO (%pred.) 98.6 (60.0–121.5)
Measurements in non-PiM and PiM resp.: FEV1 6 vs. 116 pat., RV/T
median (range), pb ¼ postbronchodilator.Pi-M versus non-PiM
There was no significant difference in age, sex and
duration of asthma between the 6 patients with a
non-PiM phenotype and the 116 patients with a PiM
phenotype (Table 1). The postbronchodilator FEV1/
VC as percentage of predicted was higher in the
patients with the non-PiM phenotype than in the
PiM-group (median (range): 105.4% (56.4–111.9) vs.
81.9% (29.3–114.6), P ¼ 0:02). There was no sig-
nificant difference between the two groups in FEV1
% predicted (non-PiM vs. PiM: 96.5% (42.2–132.3)
and 79.9% (22.4–140.4), resp., P ¼ 0:152). Multiple
linear regression analysis, corrected for possible
confounders such as age, gender and asthma
duration, showed no association between AAT
phenotype and FEV1 % predicted (P ¼ 0:26) and a
trend towards an association between a non-PiM
phenotype and a higher FEV1/VC %pred (P ¼ 0:07).PiM (n ¼ 116) P-value
44.0 (19–75) 0.17
70.7 1.00
18.5 (2–73) 0.36
79.9 (22.4–140.4) 0.12
81.9 (29.3–114.6) 0.02
110.7 (37.3–192.5) 0.16
90.2 (49.5–125.0) 0.24
LC in 4 vs. 109 pat., KCO in 6 vs. 101 pat. Data expressed as
ARTICLE IN PRESS
Deficient AAT phenotypes and persistent airflow limitation 1537Estimated decline in lung function
In the group of patients with the PiM-phenotype
there was a significant negative association be-
tween postbronchodilator FEV1 %pred. and the
duration of asthma (r ¼ 0:24, P ¼ 0:01), with
similar results for FEV1/VC %pred. (r ¼ 0:30,
b ¼ 0:34, P ¼ 0:001). The estimated decline in
FEV1 in the PiM group was 0.3% predicted per year.
In the 6 patients with the non-PiM phenotype there
was also a significant relationship between FEV1
and duration of asthma (r ¼ 0:84, P ¼ 0:04).
However, when disregarding one outlier, this
relationship was lost. Therefore, the rates of
decline between the 2 groups were not compared.Discussion
This study, performed in a large cohort of patients
with severe asthma shows that the prevalence of a
non-PiM AAT phenotype is low (4.9%). Persistent
airflow limitation is not associated with a non-PiM
phenotype in these patients. This suggests that AAT
heterozygoty is not an important contributing
factor to a rapid decline in lung function in
asthmatic patients.
This is the first study investigating the non-PiM
AAT phenotype as a risk factor of persistent airflow
limitation in non-smoking asthmatic adults. We
selected a well-characterized group of patients
with severe asthma because we expected that if
there would be an association between AAT
deficiency and persistent airflow limitation, it was
most likely to be found in this group in whom
persistent airflow limitation is a common finding.
The present study shows no association between
AAT phenotypes and lung function in these severe
asthmatic patients. These findings extend the
findings of two previous studies investigating the
relationship between AAT-phenotypes, asthma
symptoms and decline in lung function. One study
in the general population showed that a non-PiM
phenotype is not associated with a more rapid
decline in lung function,24 whereas another study in
patients with severe AAT-deficiency found no
association between the presence of asthmatic
features and an accelerated decline in lung func-
tion.19 A recent population study, however, sug-
gested that asthmatic children with reduced levels
of AAT might be prone to develop airway hyperre-
sponsiveness and reduced lung function.25 The
reason for the discrepancy between this study and
other studies might be the difference in the
selection of patients on the basis of AAT levels orAAT phenotypes. Our study shows that the pre-
valence of the non-PiM phenotype in patients with
severe asthma is comparable to the estimated
prevalence in the Dutch population (MS in Holland
4.3%, MZ 2%, SZ 0.05%)26 and fits in with the findings
in a non-selected population of asthmatic patients
in Spain.27
The results of this study might be influenced by
the selection of patients. We chose to study
patients with severe asthma, because we expected
that an association between lung function and AAT
phenotype would be easier to detect in patients
with severe asthma than in a random population
sample. The sample of patients with severe asthma
was recruited from 10 different outpatient clinics
and can therefore be considered representative of
the population of such patients within the Nether-
lands. We believe that if the selection of patients
had biased the results of our study, this would have
influenced the results towards a positive associa-
tion rather than towards a lack of association
between these two parameters. Another point of
concern is the relatively small group of patients
with a non-PiM phenotype. Given the high pre-
valence of asthmatic patients with persistent air-
flow limitation (47.5%) we expected to find a much
higher prevalence of non-PiM phenotypes. How-
ever, the finding that the prevalence of a non-PiM
phenotype was comparable to that of the normal
population supports the conclusion of the study
that a heterozygous AAT phenotype is not a risk
factor for the development of persistent airflow
limitation in asthma. Nevertheless, due to the
limited power of this study, the results need to be
confirmed by a prospective longitudinal study using
a larger asthma cohort in which the AAT phenotype
can be related to decline in lung function over
time.
In an attempt to estimate the decline in lung
function over time, we calculated the change in
FEV1 in relation to the duration of asthma for all
patients by regression analysis. Unfortunately, the
results of the regression analysis in the non-PiM
group were not reliable because of the small
sample size and uneven distribution of the data.
All patients with a non-PiM phenotype had a
postbronchodilator FEV1 within the normal range
except for one outlier. This patient with a
postbronchodilator FEV1 of 42% predicted had a
duration of asthma of 56 years. In view of the
negative association between duration of asthma
and postbronchodilator FEV1 in the group as a
whole this impaired lung function is not surprising.
Still, we cannot exclude that partial AAT deficiency
becomes a contributing factor to persistent airflow
limitation if asthma persists for several decades.
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elastase/AAT balance. Vignola et al. have demon-
strated that the levels of elastase in induced
sputum increase with the duration of asthma,
resulting in a disturbance of the elastase/AAT
balance.28 This might contribute to airway remo-
delling, in particular in patients with AAT defi-
ciency. Taken together, it is most likely that the
combination of genetic, environmental and intrin-
sic factors determines whether the decline in lung
function exceeds normal physiological levels.
This study has both pathophysiologic and clinical
implications. The results suggest that persistent
airflow limitation in asthma is not related to AAT
deficiency and subsequent development of emphy-
sema. This is supported by the lack of any
difference in CO-transfer factor between the
patients with a PiM or non-PiM phenotype. Although
the results clearly need confirmation in longitudinal
studies using larger cohorts, the present study
suggests that routine assessment of the AAT
phenotype is not indicated in patients with asthma
because it most likely does not provide additional
insight into the phenotypic expression of the
disease nor into the long-term prognosis.
In conclusion, we have shown that a hetero-
zygous (non-PiM) AAT phenotype is not likely to be a
risk factor of persistent airflow limitation in
patients with asthma. The prevalence of an
abnormal AAT phenotype in patients with severe
asthma is low, even in those with fixed airflow
limitation. Since the aetiology of fixed airflow
limitation in asthma is still far from clarified, the
search for risk factors must continue.Acknowledgements
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